Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study

BACKGROUND: Desensitization with IVIG and rituximab allows acceptable graft survival in sensitized kidney transplant recipients with preexisting donor-specific antibodies (DSAs) and a positive crossmatch. There is little published data reporting the durability of DSA removal in kidney transplant rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaffer, David, Feurer, Irene D., Crowe, Deborah, Schaefer, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946491/
https://www.ncbi.nlm.nih.gov/pubmed/27500255
http://dx.doi.org/10.1097/TXD.0000000000000570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946491/
https://www.ncbi.nlm.nih.gov/pubmed/27500255
http://dx.doi.org/10.1097/TXD.0000000000000570

Ejemplares similares